Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03530696 · ClinicalTrials.gov registry record · Phase 2
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
A Phase 2 study, sponsored by University of Arizona.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT03530696 is a Phase 2 study that has completed, run by University of Arizona. The registered enrollment target is 55 participants.
The verdict
NCT03530696, a Phase 2 study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a single arm, phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival in patients with metastatic HER2 positive breast cancer. All patients will be treated with T-DM1 with palbociclib.
Interventions
- DRUG T-DM1
- DRUG Palbociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03530696
The ClinicalTrials.gov registry entry for NCT03530696 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which T-DM1 is the first listed.
NCT03530696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03530696 about?
NCT03530696 is a clinical study titled "T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer". This is a single arm, phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival in patients with metastatic HER2 positive breast cancer. All patients will be treated with T-DM1 with palbociclib.
What is the current status of trial NCT03530696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2018-12-06. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT03530696?
The interventions under investigation include: T-DM1 (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT03530696?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.